Zobrazeno 1 - 10
of 281
pro vyhledávání: '"sibling donor"'
Autor:
Ruowen Wei, Jun Fang, Wei Shi, Xuan Lu, Yingying Wu, Shan Jiang, Ao Zhang, Shanshan Liao, Chunxia Qin, Guohui Cui, Linghui Xia
Publikováno v:
Cancer Medicine, Vol 12, Iss 9, Pp 10499-10511 (2023)
Abstract Objective To investigate the differences in efficacy and safety between haploidentical donor hematopoietic stem cell transplantation (HID‐HSCT) and matched sibling donor HSCT (MSD‐HSCT) in patients with T‐cell lymphoblastic lymphoma (T
Externí odkaz:
https://doaj.org/article/a9753f0a909742c3ae6e68e3c8accee2
Autor:
Hengwei Wu, Yeqian Zhao, Fei Gao, Jimin Shi, Yi Luo, Jian Yu, Xiaoyu Lai, Lizhen Liu, Huarui Fu, Pengxu Qian, He Huang, Yanmin Zhao
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-11 (2023)
Abstract The success of allogeneic hematopoietic stem cell transplant for hematological malignancies is heavily dependent on the availability of suitable donors. Haploidentical donor (HID) and matched sibling donor (MSD) are two important donor optio
Externí odkaz:
https://doaj.org/article/ab3b25dd21a64655a5e04cc3cd09fe6b
Autor:
Jianyun Wen, Xiaodong Wang, Libai Chen, Yuelin He, Xiaoqin Feng, Chunfu Li, Yongshen Ruan, Sixi Liu, Xuedong Wu
Publikováno v:
Hematology, Vol 27, Iss 1, Pp 310-317 (2022)
Background Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment for thalassaemia major (TM). Cord blood (CB) from a sibling has different characteristics from marrow and has potential advantages and
Externí odkaz:
https://doaj.org/article/98e6594769f14e3a9ccab826f116de9e
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sanjeev Kumar Sharma, Dharma Choudhary, Divya Doval, Vipin Khandelwal, Rasika Setia, Tina Dadu, Anil Handoo
Publikováno v:
South Asian Journal of Cancer, Vol 11, Iss 01, Pp 062-067 (2022)
Abstract Sanjeev Kumar Sharma Hematopoietic stem cell transplantation (HSCT) is the preferred treatment for high-risk and relapsed/refractory hematological malignancies. Moreover, with the improved supportive care and increasing acceptance of haplo
Externí odkaz:
https://doaj.org/article/8cba181a40004539970cf9b9458ea26f
Autor:
Mahmoud Hammad, Hanafy Hafez, Iman Sidhom, Dina Yassin, Sherine Salem, Khaled Alsheshtawi, Nayera Hamdy, Nahla Elsharkawy, Alaa Elhaddad
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionAllogeneic hematopoietic stem cell transplantation (HSCT) is widely used for high-risk acute lymphoblastic leukemia (ALL) patients in their first complete remission (CR1), and for relapsed patients in second complete remission (CR2).Patie
Externí odkaz:
https://doaj.org/article/bed709c504ff4fb5a1544eeaea691594
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Recent studies have shown that haploidentical hematopoietic stem cell transplantation supported by third-party cord blood (haplo-cord-HSCT) results in rapid hematopoietic recovery, low incidences of graft-versus-host disease (GVHD), and relapse of he
Externí odkaz:
https://doaj.org/article/c5fd8df4ad2f4f29967abf4f51dd5022
Publikováno v:
Cancer Management and Research, Vol Volume 12, Pp 12287-12300 (2020)
Zheng-Yang Song, Han-Yun Ren, Yu-Jun Dong, Yuan Li, Yue Yin, Yu-Hua Sun, Qian Wang, Wei-Lin Xu, Wei Liu, Jin-Ping Ou, Ze-Yin Liang Department of Hematology, Peking University First Hospital, Peking University, Beijing, People’s Republic of ChinaCor
Externí odkaz:
https://doaj.org/article/c4661926ae244f059fb2d206ce68c204
Autor:
Jiafu Huang, Fen Huang, Zhiping Fan, Na Xu, Li Xuan, Hui Liu, Pengcheng Shi, Ling Jiang, Yu Zhang, Jing Sun, Qifa Liu
Publikováno v:
Cancer Medicine, Vol 9, Iss 17, Pp 6244-6255 (2020)
Abstract Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is a potentially curative therapeutic option for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Increasing data suggest that haploidentical donor
Externí odkaz:
https://doaj.org/article/3b72e83a8c784291bebe8b2486bb575b
Autor:
Ying-Jun Chang, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Wei-Han, Yu-Qian Sun, Chen-Hua Yan, Fei-Fei Tang, Xiao-Dong Mo, Yan-Rong Liu, Kai-Yan Liu, Xiao-Jun Huang
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-13 (2020)
Abstract Background Previous reports suggest a benefit associated with haploidentical donor transplantation (HIDT) compared to matched sibling donor transplantation (MSDT) in certain contexts, and the choice of optimal candidates warrants further inv
Externí odkaz:
https://doaj.org/article/18f84cca74ae4b59bcc572bb901e2791